Alfonso Berrocal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer

Ricardo Hitt, Juan J. Grau, Antonio López–Pousa et al. · Annals of Oncology · 2013 · 345 citations

Neck Cancer, Neoadjuvant Therapy, Radiation Therapy +11

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella et al. · Journal of Clinical Oncology · 2022 · 124 citations

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR

Miguel Vizoso, Humberto J. Ferreira, Paula López-Serra et al. · Nature Medicine · 2015 · 113 citations · Full text

Medicine, Melanoma, Epigenetic Activation +5

Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC)

Ricardo Hitt, Juan J. Grau, Antonio López–Pousa et al. · Journal of Clinical Oncology · 2009 · 69 citations

Neck Cancer, Neoadjuvant Therapy, Cancer Management +18